Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 8/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 5/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4844297 | 0.91 | JAK1 (0.44) | JAK1DHODHJAK2JAK3IKBKE | |
| SCHEMBL4840913 | 0.83 | ACHE (0.55) | DHODHCHEK2IKBKETBK1PARP1 | |
| SCHEMBL4838086 | 0.81 | TBK1 (0.63) | JAK1DHODHIKBKETBK1ACHE | |
| SCHEMBL4839593 | 0.81 | MEN1 (0.48) | JAK1JAK2JAK3IKBKETBK1 | |
| SCHEMBL6219742 | 0.80 | CHEK2 (0.49) | JAK1JAK2JAK3CHEK2SYK | |
| SCHEMBL4843765 | 0.76 | TNKS (0.50) | PARP1 | |
| SCHEMBL23140719 | 0.71 | HDAC3 (0.44) | JAK1ADORA2A | |
| SCHEMBL4843809 | 0.69 | CHEK2 (0.50) | DHODHCHEK2 | |
| SCHEMBL28598657 | 0.69 | CASP2 (0.44) | ADORA2A | |
| SCHEMBL4841957 | 0.68 | TBK1 (0.64) | DHODHIKBKETBK1ACHEADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | JAK1 291/4885DHODH 3294/4885AURKA 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.